SEHA Launches Innovative Rilonacept Treatment For Idiopathic Pericarditis And Still’s Disease In The UAE

Tawam Hospital, under the Department of Health – Abu Dhabi and part of SEHA and PureHealth, has introduced a new treatment for idiopathic pericarditis and Still’s disease. This marks the first use of such therapy in the UAE and GCC. The treatment involves Rilonacept, a drug that blocks interleukin-1, reducing inflammation-related symptoms like fever and pain.

Two young Emirati patients have benefited from this innovative approach, recovering from conditions previously resistant to treatment. The Department of Health – Abu Dhabi has approved this drug, highlighting its commitment to medical innovation and ensuring timely access to advanced therapies.

Dr. Khalid Abdalla Alnaqbi, Consultant Physician & Chief of Rheumatology at Tawam Hospital, expressed pride in offering these treatments locally. He stated, "Both patients had sought medical attention abroad. We are proud to deliver the latest innovative treatments here in the UAE." This achievement underscores Tawam Hospital's role as a key referral hub for complex cases in the region.

Dr. Dalal Saeed Al Mansoori, Chief Medical Officer at Tawam Hospital, emphasized patient-centric care. She noted, "Our priority is always the patient. By making cutting-edge therapies available locally, we are not only improving outcomes but also giving hope to patients and their families facing challenging conditions."

This development positions SEHA as a leader in regional healthcare innovation. It supports the UAE's vision of providing world-class medical care domestically by delivering advanced strategies for rare and complex diseases.

The introduction of Rilonacept therapy at Tawam Hospital signifies a significant step forward in healthcare within the UAE. It reflects an ongoing commitment to enhancing patient outcomes through local access to global standards of care.

With inputs from WAM